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1 min; 47°C, 2 min; 72°C, 2 min), the product was diluted (1:500) and 1 l was amplified in a second round of PCR (30 cycles). Using the CEAH2 primer for two rounds of PCR someThe recurrent t(6;9)(p23;q34), found with low frequency in times resulted in background amplification of CAN. In subacute myeloid leukemia (AML) and myelodysplastic synsequent studies on bone marrow samples from another t(6;9) drome, 1,2 creates a fusion between two genes, DEK and CAN. 3 patient, we found that performing a semi-nested PCR with the The resulting chimeric DEK-CAN mRNA can be detected with CAN antisense primer CEAH1 for the first-round, followed by the reverse transcription-polymerase chain reaction (RT-PCR).
1
CEAH2 for the second-round, gave more consistent results. This technique allowed sensitive detection of residual leukemic
One-eighth of the PCR product was resolved by electrocells after treatment in a t(6;9) patient. 4 Here, we describe for phoresis through 1.5% agarose gels. The identity of the PCR the first time the complete absence of DEK-CAN transcripts in fragments was confirmed by hybridization of Southern blots post-transplantation samples from a patient who has been in with specific oligonucleotide probes, 1 allowing the detection continuous complete remission for more than 2 years.
of one t(6;9) positive cell in 5 × were negative for DEK-CAN. Due to low RNA yield, the samvalues, and LDH 1363 IU (normal 420-920 IU). The bone ple taken 4 months after BMT had to be amplified for four marrow was replaced by FAB type M2 blast cells, which additional cycles in the second-round of PCR, resulting in stained positively for myeloperoxidase and Sudan black, and about a 10-fold decrease in sensitivity. negatively for ␣-naphthyl butyrate and chloroacetate esterase.
The DEK-CAN RT-PCR assay detects one patient cell in Auer rods were not noted. Chromosome analysis revealed a 5 × 10 4 normal cells, which is 2-20 times less sensitive than clonal abnormality in 19 of 20 metaphases: 46,XY, similar assays for other fusion transcripts, such as BCR-ABL t(6;9)(p23;q34). Immunophenotype studies of blasts were conand AML1-ETO. [6] [7] [8] This degree of sensitivity probably reflects sistent with myeloid lineage: CD33 + (97%), CD13 + (92%) and low levels of DEK-CAN mRNA in leukemic cells.
CD15
+ (52%). The patient was enrolled on the AML91 protoOur PCR results show that samples from a patient who has col. 5 Hematologic remission, including normal karyotype, achieved complete remission following allogeneic BMT do was achieved after two courses of 2-CDA followed by daunonot contain detectable amounts of DEK-CAN transcript. The mycin, Ara-C, and etoposide. The patient underwent allochemotherapy alone decreased but did not completely eradigeneic bone marrow transplantation (BMT) from his HLAcate the leukemic cells. These data support the clinical obseridentical brother in April 1994. The BMT conditioning regivation that t(6;9) patients respond poorly to chemotherapy, men included total body irradiation and high-dose chemowith a median survival of less than 1 year from diagnosis, 2 therapy, and cyclosporin and pentoxifylline were adminisand that transplantation may be the most effective therapy for tered to prevent graft-versus-host disease (GVHD). The patient t(6;9) AML (our unpublished observation). required a short course of prednisone for probable intestinal
In other translocation-related leukemias, such as t(9;22) GVHD.
chronic myeloid leukemia and t(15;17) acute promyelocytic Collection of bone marrow cells, cDNA preparation and leukemia, the presence of fusion transcripts after treatment PCR conditions for the evaluation of DEK-CAN transcripts can be predictive of relapse, while serially negative PCR tests were essentially as described, 1 using primer set 2, with the are associated with prolonged disease-free survival (Ref. 9 and following modifications: first-strand cDNA was synthesized references therein). 9,10-13 However, persistence of fusion tranfrom 2 g instead of 5 g total RNA. In the PCR a new CAN scripts in AML with t(8;21), APL with t(15;17) and CML with t(9;22) in prolonged complete remission has also been described, and the issue is still controversial. [14] [15] [16] [17] In the only Our data show that in a child with t(6;9) AML long-term 
